title: Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32:320-1) and Drs. Marr and Boeckh (Clin Infect Dis 2001; 32:321).
authors.forename: J H
authors.initials: JH
authors.lastname: Rex
authors.forename: T J
authors.initials: TJ
authors.lastname: Walsh
authors.forename: J D
authors.initials: JD
authors.lastname: Sobel
authors.forename: S G
authors.initials: SG
authors.lastname: Filler
authors.forename: P G
authors.initials: PG
authors.lastname: Pappas
authors.forename: W E
authors.initials: WE
authors.lastname: Dismukes
authors.forename: J E
authors.initials: JE
authors.lastname: Edwards
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D005335:Fever of Unknown Origin / Q000188:drug therapy / Q000209:etiology; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D009503:Neutropenia / Q000150:complications* / Q000188:drug therapy
chemical_list: D000935:Antifungal Agents; D015725:Fluconazole